1887

Abstract

Introduction:

is a newly described species in the genus .

Case presentation:

We describe here a clinical case of chromoblastomycosis in a 66‐year‐old man who presented a 3‐year history of leg lesions. was identified by morphological and molecular methods. Four months of treatment with itraconazole (300 mg daily) significantly improved the lesions.

Conclusion:

To the best of our knowledge, this case represents the first clinical case of described in France. Particular attention should be paid to microscopic examination for fungal cultures in order to avoid confusion with a contaminating fungus. Moreover, recurrent, wide and deep biopsies should be performed to monitor the evolution of the lesions.

  • This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/).
Loading

Article metrics loading...

/content/journal/jmmcr/10.1099/jmmcr.0.004218
2014-12-01
2024-11-10
Loading full text...

Full text loading...

/deliver/fulltext/jmmcr/1/4/jmmcr004218.html?itemId=/content/journal/jmmcr/10.1099/jmmcr.0.004218&mimeType=html&fmt=ahah

References

  1. Alvarez E., Garcia‐Hermoso D., Sutton D.A., Cano J.F., Stchigel A.M., Hoinard D., Fothergill A.W., Rinaldi M.G., Dromer F., Guarro J. ( 2010). Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea . J Clin Microbiol 48:4410–4416 [CrossRef]
    [Google Scholar]
  2. Ameen M. ( 2009). Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol 34:849–854 [CrossRef]
    [Google Scholar]
  3. Bonifaz A., Carrasco‐Gerard E., Saúl A. ( 2001). Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 44:1–7 [CrossRef]
    [Google Scholar]
  4. Gupta A.K., Taborda P.R., Sanzovo A.D. ( 2002). Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 40:529–534 [CrossRef]
    [Google Scholar]
  5. López Martínez R., Méndez Tovar L.J. ( 2007). Chromoblastomycosis. Clin Dermatol 25:188–194 [CrossRef]
    [Google Scholar]
  6. Najafzadeh M.J., Sun J., Vicente V., Xi L., van den Ende A.H.G.G., de Hoog G.S. ( 2010). Fonsecaea nubica sp. nov, a new agent of human chromoblastomycosis revealed using molecular data. Med Mycol 48:800–806 [CrossRef]
    [Google Scholar]
  7. Najafzadeh M.J., Sun J., Vicente V.A., Klaassen C.H.W., Bonifaz A., van den Ende A.H.G.G., Menken S.B.J., Sybren de Hoog G. ( 2011). Molecular epidemiology of Fonsecaea species. Emerg Infect Dis 17:464–469 [CrossRef]
    [Google Scholar]
  8. Queiroz‐Telles F., McGinnis M.R., Salkin I., Graybill J.R. ( 2003). Subcutaneous mycoses. Infect Dis Clin North Am 17:59–85 viii [CrossRef]
    [Google Scholar]
  9. Queiroz‐Telles F., Esterre P., Perez‐Blanco M., Vitale R.G., Salgado C.G., Bonifaz A. ( 2009). Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol 47:3–15 [CrossRef]
    [Google Scholar]
  10. Slesak G., Inthalad S., Strobel M., Marschal M., Hall M.J., Newton P.N. ( 2011). Chromoblastomycosis after a leech bite complicated by myiasis: a case report. BMC Infect Dis 11:14 [CrossRef]
    [Google Scholar]
  11. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)( 2008). EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia‐forming moulds. Clin Microbiol Infect 14:982–984 [CrossRef]
    [Google Scholar]
  12. Sun J., Najafzadeh M.J., Gerrits van den Ende A.H.G., Vicente V.A., Feng P., Xi L., De Hoog G.S. ( 2012). Molecular characterization of pathogenic members of the genus Fonsecaea using multilocus analysis. PLoS One 7
    [Google Scholar]
  13. Ungpakorn R., Reangchainam S. ( 2006). Pulse itraconazole 400 mg daily in the treatment of chromoblastomycosis. Clin Exp Dermatol 31:245–247 [CrossRef]
    [Google Scholar]
/content/journal/jmmcr/10.1099/jmmcr.0.004218
Loading
/content/journal/jmmcr/10.1099/jmmcr.0.004218
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error